July 25, 2016 1:46 AM ET

Life Sciences Tools and Services

Company Overview of PureTech Health plc

Company Overview

PureTech Health plc, a science-driven healthcare company, focuses on developing technologies that seek to address healthcare markets. The company, through its subsidiaries and operating companies, engages in developing microbiome immune system drug-discovery platform and drug candidates for the treatment of immune-mediated diseases; and products that seek to induce weight loss and potentially enhance glycaemic control through an orally administered capsule. It is also developing technology and products for the screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric di...

501 Boylston Street

Suite 6102

Boston, MA 02116

United States

Founded in 2015

69 Employees

Phone:

617-482-2333

Fax:

617-482-3337

Key Executives for PureTech Health plc

Co-Founder, Chief Executive Officer and Executive Director
Age: 45
Total Annual Compensation: $614.9K
Executive Vice President of Legal, Finance & Operations and Executive Director
Age: 46
Total Annual Compensation: $410.4K
Compensation as of Fiscal Year 2014.

PureTech Health plc Key Developments

PureTech Health plc Announces Executive Changes

PureTech Health plc announced the appointment of Feng Zhang, Ph.D. to its Scientific Advisory Board (SAB). The Company has also appointed Jeff Stevens, as Vice President of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, Dr. PH, Executive Vice President of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., Former Senior Vice President and Head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., Global Head of Diabetes Research & Development at Sanofi. Feng Zhang, Ph.D., will join PureTech as a member of the Company’s SAB. Jeff Stevens will join PureTech as Vice President of Growth Strategy & Operations. In this role, he will be helping to refine and prioritise indications and commercial opportunities for PureTech’s growth stage platforms. Mr. Stevens has been involved with the global healthcare industry for nearly 25 years. Meghan Fitzgerald, DrPH, will join PureTech as a senior advisor. She is the Executive Vice President of Strategy, M&A and Health Policy at Cardinal Health and is a member of Cardinal Health’s executive committee. She is an expert on a wide array of healthcare topics and trends, including specialty healthcare and healthcare policy. Dr. Fitzgerald leads Cardinal Health's Corporate Strategy team and previously was the President of Cardinal Health Specialty Solutions, a specialty healthcare business that offers services for healthcare providers, payers, and pharmaceutical and biotech industries. Philip J. Larsen, M.D., Ph.D., will join PureTech as a senior advisor. He is the Global Head of Diabetes R&D at Sanofi. He has 20 years of pharmaceutical and biotechnology industry experience in the field of diabetes and obesity. Previously he was Head of the Neuroendocrine Pharmacology Department at Novo Nordisk and was Chief Scientific Officer for diabetes research at Eli Lilly. Atul Pande, M.D., will join PureTech as a senior advisor. Dr. Pande has more than two decadesof experience in drug development. He has led several programmes in neurosciences, respiratory, HIV, oncology and cardiovascular therapy areas. Dr. Pande is the former Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline and has been active in the development of multiple important central nervous system drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories.

PureTech Health plc Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 09:30 AM

PureTech Health plc Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 09:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Daphne Zohar, Co-Founder, Chief Executive Officer and Executive Director.

PureTech Launches "Alivio Therapeutics" and Advances Novel Approach for Treating Inflammatory Disease

PureTech Health announced the launch of Alivio Therapeutics, which is developing a novel technology for the targeted treatment of inflammatory disorders. The technology is based on an innovative hydrogel material that is designed to adhere to and deliver drugs to inflamed tissue based on the degree of inflammation. This approach may help overcome major technical challenges in the field, enabling new therapies that have the potential to address multiple acute and chronic inflammatory disorders.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 6, 2016
Vedanta Biosciences, Inc.
Private Placement
January 22, 2016
Akili Interactive Labs, Inc.
Private Placement
December 17, 2015
Gelesis, Inc.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PureTech Health plc, please visit www.puretechhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.